Internal Medicine - Issue 11/2014
Reviews
926
931
Prevention of cardiovascular diseases in clinical practice: is it possible to achieve improvement?
Tomáš Štulc, Michaela Šnejdrlová, Richard Češka
937
Residual cardiovascular risk markers
Hana Rosolová, Barbora Nussbaumerová
942
New aspects of hormone replacement therapy
Tomáš Fait
949
News in lipid lowering treatment
Michal Vrablík, Richard Češka
958
Non-pharmacological treatment – results from Poděbrady
Lukáš Zlatohlávek, Michal Vrablík, Zuzana Urbanová, Hana Pejšová, Jaroslav Hubáček, Richard, Češka
963
Familial hypercholesterolemia – past and present.
My experiences and findings in our group of patients with familial hypercholesterolemia
My experiences and findings in our group of patients with familial hypercholesterolemia
Richard Češka, Michal Vrablík, Tereza Altschmiedová, Martina Prusíková, Zuzana Urbanová, Josef Šobra
970
LDL-apheresis in the treatment familial hypercholesterolemia
Vladimír Bláha, Milan Bláha, Miriam Lánská, Eduard Havel, Pavel Vyroubal, Zdeněk Zadák, Pavel Žák, Luboš Sobotka
977
Extended options of anticoagulant treatment in thromboembolism
Debora Karetová, Jan Bultas
985
What do have arterial and venous disease in common?
Jan Piťha, Ondřej Auzký, Karel Roztočil
991
Cardiovascular risk profile in 40-year old men and 50-year old women in the Czech Republic: results of a cross-sectional survey
Michal Vrablík, Zdeněk Chmelík, Věra Lánská
Actualities
Internal Medicine
2014 Číslo 11
Najčítanejšie v tomto čísle
- New aspects of hormone replacement therapy
- LDL-apheresis in the treatment familial hypercholesterolemia
- New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes
- Extended options of anticoagulant treatment in thromboembolism